Compounded Semaglutide: Safety, Cost, and Where to Get It

What compounded semaglutide actually is

Compounded semaglutide is a version of the semaglutide molecule prepared by a compounding pharmacy rather than manufactured by Novo Nordisk (the maker of Wegovy and Ozempic). Compounding pharmacies are licensed facilities that create customized medications based on prescriptions. They operate under FDA oversight through sections 503A (patient-specific compounding) and 503B (outsourcing facilities that can compound without individual prescriptions) of federal law.

The semaglutide molecule in a compounded product is the same active pharmaceutical ingredient. However, compounded products may differ from branded products in formulation, inactive ingredients, concentration, and quality control processes. This is why pharmacy quality matters enormously. A compounded product from a well-run, inspected 503B facility is a very different proposition from one sourced through an unverified online supplier.

ClearlyMeds is an independent editorial team. Revenue never influences our rankings, and every guide is written to help readers understand tradeoffs in plain English rather than push a single provider.

• Same active ingredient as Wegovy and Ozempic
• Prepared by compounding pharmacies under FDA oversight
• Quality varies significantly between pharmacies
• Not FDA approved as a finished product

Safety considerations and quality markers

The safety of compounded semaglutide depends almost entirely on the pharmacy producing it. Key quality markers to look for: the pharmacy should hold a valid state license, be registered as a 503A or 503B facility with the FDA, follow current Good Manufacturing Practices (cGMP), conduct third-party potency and sterility testing, and have a clean inspection history. Patients can verify pharmacy licensure through their state's Board of Pharmacy.

Red flags include providers who refuse to disclose their pharmacy partner, pharmacies with FDA warning letters, products shipped without proper cold chain handling, and prices that seem too low to support quality manufacturing. The cheapest compounded semaglutide is not necessarily the best value if quality controls are inadequate.

Providers like Eden, SkinnyRx, and Mochi Health work with identified compounding pharmacies, but patients should still independently verify the pharmacy's credentials and ask about testing protocols.

Cost comparison: compounded vs brand-name

The cost difference between compounded and brand-name semaglutide is substantial. Brand-name Wegovy has a list price exceeding $1,300 per month without insurance. With good insurance coverage, the out-of-pocket cost can drop to $25 to $150 per month, but many patients face denied prior authorizations, high deductibles, or plans that exclude weight loss medications entirely.

Compounded semaglutide typically costs $150 to $400 per month through telehealth providers, with the price varying based on dose level, provider fees, and pharmacy. This represents savings of $800 or more per month compared to brand-name cash pricing. For uninsured patients or those with inadequate coverage, this cost difference is the primary reason compounded options exist.

When comparing costs, patients should look at the total monthly expense including consultation fees, medication, shipping, and any required lab work. Some providers advertise low medication prices but charge separately for consultations or follow-up visits. Transparent all-in pricing is a positive signal about a provider's business practices.

The regulatory landscape in 2026

The FDA's approach to compounded semaglutide has evolved as the GLP-1 market has grown. During the semaglutide shortage period (2023 to 2025), compounding was broadly permitted under shortage provisions. As supply has stabilized, the FDA has increased enforcement, particularly targeting pharmacies that fail to meet quality standards or that market compounded products in ways that blur the line with branded drugs.

As of April 2026, compounded semaglutide remains available through properly licensed pharmacies, but patients should be aware that the regulatory environment could shift. The FDA has signaled continued focus on compounding quality and on protecting the branded drug market. Patients who rely on compounded access should choose providers that communicate proactively about regulatory changes and have contingency plans (such as transitioning patients to branded pathways or alternative medications if compounding access narrows).

The practical advice for patients: compounded semaglutide is a legitimate option today, but it is not guaranteed to remain available in its current form indefinitely. Patients should factor regulatory risk into their provider choice and avoid providers who dismiss FDA enforcement as irrelevant.

How to choose a compounded semaglutide provider

When evaluating telehealth providers offering compounded semaglutide, patients should assess five factors: pharmacy transparency (does the provider disclose who compounds their medication?), clinical oversight (is a licensed clinician reviewing your case and managing dosing?), pricing clarity (is the total cost clear upfront?), follow-up access (can you reach a clinician if side effects occur?), and regulatory awareness (does the provider acknowledge the evolving regulatory landscape?).

Among current providers, Eden is known for transparent pricing and fast prescribing. SkinnyRx offers competitive cash-pay pricing on compounded options. Mochi Health combines compounded access with a clinical platform that includes follow-up support. Each has different strengths depending on the patient's priorities.

This guide is educational and not a substitute for personal medical advice. Eligibility, contraindications, and monitoring needs differ across individuals, which is why treatment decisions should be reviewed with a licensed clinician.